Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 46 Lymphoma, Non-Hodgkin 15 Lymphoma 15 Leukemia, B-Cell 14 Leukemia 14 Lymphoma, Follicular 11 Recurrence 9 Neoplasms 7 Lymphoma, Large B-Cell, Diffuse 7 Lymphoma, Mantle-Cell 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Burkitt Lymphoma 5 Lymphoma, B-Cell 4 Bronchiolitis Obliterans Syndrome 4 Waldenstrom Macroglobulinemia 3 Lymphoma, B-Cell, Marginal Zone 3 Hodgkin Disease 2 Hematologic Neoplasms 2 Thrombocytopenia 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Paraproteinemias 1 Oncology Patients Receiving Chemotherapy 1 Melanoma 1 Lymphocytosis 1 Lymphadenopathy 1 Leukemia, Prolymphocytic 1 Leukemia, Lymphoid 1 Fever 1 Fatigue 1 Disease 1

Interventions

ofatumumab 1 ocrelizumab 1 obinutuzumab 1 ibritumomab tiuxetan 1 Rituximab 1 Paclitaxel 1 Diphenhydramine 1 Cetirizine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Oncology Patients Receiving Chemotherapy × ofatumumab × Clear all

NCT04189588 2023-10-06

versus

TerSera Therapeutics LLC

Phase 2 Completed

34 enrolled 11 charts

Oncology Patients Receiving Chemotherapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡